Orgenesis (Orgenesis) GF Value : $0.03 (As of May. 06, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), Orgenesis's share price is $0.527. Orgenesis's GF Value is $0.03. Therefore, Orgenesis's Price-to-GF-Value for today is 17.57.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Orgenesis is Significantly Overvalued.

Orgenesis (NAS:ORGS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Orgenesis's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.527	/	0.03
	=	17.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis GF Value Related Terms

Thank you for viewing the detailed overview of Orgenesis's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (Orgenesis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

45O:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Executives

Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452